Should I buy Veracyte, Inc. (VCYT) stock or is it too late?

Veracyte, Inc. · Health Care · price $45

See the full Veracyte, Inc. (VCYT) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 69% of its targets hit on this sector (49 calls tested). It aims for $65 (+44 %), call made on June 30, 2026, maturing on June 30, 2027 (59 d ago).

The 1 reliable analyst $65+44 %

The 7 other firms $52+15 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $65 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Veracyte, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Needham	62 %	+16.3 %	21	$69 +52%
Stephens & Co.	29 %	-2.8 %	7	$55 +22%
Morgan Stanley	46 %	-3.5 %	13	$44 -3%
SVB Leerink	40 %	-14.4 %	10	—
Raymond James	0 %	-23.9 %	7	—

In short — Should you invest in Veracyte, Inc.? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $53, i.e. +17%), and the most reliable on VCYT targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
Median price target $53, i.e. +17% from the current price ($45).
The most reliable firm on VCYT, UBS (100% hit rate, 4 scored calls), targets $52 (call made on May 7, 2026, maturing on May 7, 2027) (+15%) in its most recent call, and $48 (call made on November 6, 2025, maturing on November 6, 2026) (+6%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 1 is neutral and 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on VCYT

Median target $53 (+17%) · 8 ratings · Buy consensus

Strong Buy00%

Buy675%

Hold113%

Sell113%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Veracyte, Inc. now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $53 (+17%), and UBS (most reliable on VCYT, 100%) targets $52. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Veracyte, Inc.?

Not according to analysts: the median target ($53) is still +17% above the current price ($45) (most reliable on VCYT: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Veracyte, Inc. still worth investing in?

It depends on the gap between the price ($45) and its estimated value: analysts target $53 on median (+17%), with 75% buys (most reliable on VCYT: UBS, 100%). Cross-check with their real reliability on VCYT and the cautions above. Information, not advice.

What's the main risk in buying VCYT?

The consensus is not unanimous: of 8 ratings, 1 is neutral and 1 is a sell.

→ Go deeper: the full Veracyte, Inc. profile (consensus, analyst reliability, price target, performance).